Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5640740 | 0.88 | CYP1A2 (0.60) | ALDH1A1KDM4ECYP3A4TSHRNPC1 | |
| SCHEMBL10960717 | 0.84 | ALDH1A1 (0.49) | ALDH1A1KDM4EKMT2ACYP3A4TSHR | |
| SCHEMBL5668088 | 0.83 | GPR35 (0.45) | ALDH1A1KDM4EKMT2ATSHRNPC1 | |
| SCHEMBL1341858 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KDM4EKMT2ACYP3A4TSHR | |
| SCHEMBL3957985 | 0.82 | FLT3 (0.50) | ALDH1A1KDM4EKMT2ANPC1LMNA | |
| SCHEMBL10619771 | 0.82 | ALDH1A1 (0.62) | ALDH1A1KDM4EKMT2ACYP3A4TSHR | |
| SCHEMBL28338065 | 0.82 | CYP3A4 (0.40) | ALDH1A1KDM4EKMT2ACYP3A4TSHR | |
| SCHEMBL18181653 | 0.82 | ALDH1A1 (0.47) | ALDH1A1KDM4EKMT2ATSHRNPC1 | |
| SCHEMBL3884042 | 0.82 | ALDH1A1 (0.49) | ALDH1A1KDM4EKMT2ANPC1L3MBTL1 | |
| SCHEMBL5068190 | 0.81 | MAPT (0.58) | ALDH1A1KDM4EKMT2ACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| CN-101130526-B | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK AS | 2013-07-10 | — | — | CN | disclosed |
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-7541373-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | disclosed |
| US-7384967-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| EP-1324981-A2 | AMINOPYRIDINYL-, AMINOGUANIDINYL- AND ALKOXYGUANIDINYL- SUBSTITUTED PHENYL ACETAMIDES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20030073833-A1 | Aminopyridyl-substituted phenyl acetamides as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6521663-B2 | For oral administration or embedded or otherwise attached to medical devices for blood collection and/or treatment | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020061872-A1 | Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS | 2002-05-23 | — | — | US | disclosed |
| WO-2002028825-A2 | AMINOPYRIDINYL-, AMINOGUANIDINYL- AND ALKOXYGUANIDINYL- SUBSTITUTED PHENYL ACETAMIDES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-04-11 | — | — | WO | disclosed |
| US-4587259-A | Miticidal 2-(2-methyl-2,3-dihydro-benzofuran-7-yl)hydrazinecarboxylic acid esters | SHELL OIL COMPANY (US) | 1986-05-06 | — | — | US | disclosed |
| US-4550121-A | AGRICULTURE | SHELL OIL COMPANY (US) | 1985-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | ALDH1A1 257/4885KDM4E 3168/4885KMT2A 894/4885 |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | GCK, GCKR, PDK2 | ALDH1A1 192/4885KDM4E 992/4885KMT2A 1526/4885 |
| US-20020061872-A1 | Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | TFPI, PLG, PLAT | ALDH1A1 3201/4885KDM4E 1651/4885KMT2A 1347/4885 |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | ALDH1A1 192/4885KDM4E 992/4885KMT2A 1526/4885 |
| US-20030073833-A1 | Aminopyridyl-substituted phenyl acetamides as protease inhibitors | TFPI, F12, PLAT | ALDH1A1 2765/4885KDM4E 1822/4885KMT2A 1131/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | ALDH1A1 192/4885KDM4E 992/4885KMT2A 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.